Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU

K. Fischer, G. Kenet, K. Kurnik, M. Carcao, J. Oldenburg, T. Stamm-Mikkelsen, AR. Cid Haro, M. Koskenvuo, J. Blatny, C. Königs

. 2024 ; 8 (2) : 369-377. [pub] 20240123

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24007531

Prevention of bleeding and its consequences is the main goal of hemophilia treatment and determines treatment choices for patients who develop inhibitors. To assess bleeding before and during immune tolerance induction (ITI) and its association with ITI regimen and inhibitor titer, we selected and analyzed data on patients receiving high-titer inhibitors from the international prospective PedNet cohort study. In total, 222 patients with severe hemophilia A and inhibitor titers of >5 Bethesda units (BU) were followed from the first positive to the first negative inhibitor result (median overall follow-up, 1.7 years). Mean annual (joint) bleeding rates (AJBR) and 95% confidence intervals (CIs) were compared according to treatment and inhibitor titer using multivariable negative binomial regression. Before ITI, 115 patients showed an ABR of 6.1 (5.0-7.4) and an AJBR 2.6 (2.1-3.2). Bleeding was independent of inhibitor titer. During ITI, 202 patients had an ABR of 4.4 (3.9-5.1) and an AJBR of 1.7 (1.5-2.0). AJBR during ITI increased with inhibitor titer (hazard ratio [HR] for ≥200 BU vs 5 to 39 BU [4.9; CI, 3.2-7.4]) and decreased with daily ITI infusions (HR, 0.4; CI, 0.3-0.6) or activated prothrombin complex concentrate prophylaxis (HR, 0.4; CI, 0.2-0.8), whereas ITI dose and recombinant activated factor VII prophylaxis did not independently affect bleeding. These data provide evidence for a protective effect of repeated FVIII infusions (ITI) on bleeding in patients who have developed inhibitors; these data should be used to plan ITI and/or serve as a comparator for prophylaxis with nonreplacement therapy.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007531
003      
CZ-PrNML
005      
20240423160035.0
007      
ta
008      
240412s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/bloodadvances.2023011442 $2 doi
035    __
$a (PubMed)38214949
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Fischer, Kathelijn $u Center for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek University Medical Center Utrecht, Utrecht, The Netherlands $1 https://orcid.org/0000000171266613
245    10
$a Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU / $c K. Fischer, G. Kenet, K. Kurnik, M. Carcao, J. Oldenburg, T. Stamm-Mikkelsen, AR. Cid Haro, M. Koskenvuo, J. Blatny, C. Königs
520    9_
$a Prevention of bleeding and its consequences is the main goal of hemophilia treatment and determines treatment choices for patients who develop inhibitors. To assess bleeding before and during immune tolerance induction (ITI) and its association with ITI regimen and inhibitor titer, we selected and analyzed data on patients receiving high-titer inhibitors from the international prospective PedNet cohort study. In total, 222 patients with severe hemophilia A and inhibitor titers of >5 Bethesda units (BU) were followed from the first positive to the first negative inhibitor result (median overall follow-up, 1.7 years). Mean annual (joint) bleeding rates (AJBR) and 95% confidence intervals (CIs) were compared according to treatment and inhibitor titer using multivariable negative binomial regression. Before ITI, 115 patients showed an ABR of 6.1 (5.0-7.4) and an AJBR 2.6 (2.1-3.2). Bleeding was independent of inhibitor titer. During ITI, 202 patients had an ABR of 4.4 (3.9-5.1) and an AJBR of 1.7 (1.5-2.0). AJBR during ITI increased with inhibitor titer (hazard ratio [HR] for ≥200 BU vs 5 to 39 BU [4.9; CI, 3.2-7.4]) and decreased with daily ITI infusions (HR, 0.4; CI, 0.3-0.6) or activated prothrombin complex concentrate prophylaxis (HR, 0.4; CI, 0.2-0.8), whereas ITI dose and recombinant activated factor VII prophylaxis did not independently affect bleeding. These data provide evidence for a protective effect of repeated FVIII infusions (ITI) on bleeding in patients who have developed inhibitors; these data should be used to plan ITI and/or serve as a comparator for prophylaxis with nonreplacement therapy.
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé $7 D006801
650    12
$a hemofilie A $x komplikace $7 D006467
650    _2
$a kohortové studie $7 D015331
650    _2
$a prospektivní studie $7 D011446
650    _2
$a faktor VIII $7 D005169
650    _2
$a imunologická tolerance $7 D007108
650    _2
$a krvácení $x etiologie $7 D006470
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kenet, Gili $u The Israel National Hemophilia Center & Thrombosis Institute, Sheba Medical Center & The Amalia Biron Thrombosis Research Institute, Tel Aviv University, Tel Aviv-Yafo, Israel
700    1_
$a Kurnik, Karin $u Department of Paediatric Haemostasis, University Children's Hospital, Munich, Germany
700    1_
$a Carcao, Manuel $u Division of Haematology/Oncology, Hospital for Sick Children, Toronto, Canada $1 https://orcid.org/0000000153501763
700    1_
$a Oldenburg, Johannes $u Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Bonn, Germany
700    1_
$a Stamm-Mikkelsen, Torben $u Aarhus University Hospital, Department of Pediatrics and Adolescent Medicine, Aarhus, Denmark
700    1_
$a Cid Haro, Ana Rosa $u Haemostasia and Thrombosis Unit, Hospital Universitario y Politécnico La Fe, Valencia, Spain
700    1_
$a Koskenvuo, Minna $u Division of Hematology-Oncology and Stem Cell Transplantation, New Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
700    1_
$a Blatny, Jan $u Department of Paediatric Haematology and Biochemistry, University Hospital and Masaryk University Brno, Brno, Czech Republic
700    1_
$a Königs, Christoph $u University Hospital Frankfurt, Goethe University, Department of Pediatrics and Adolescent Medicine, Frankfurt, Germany
773    0_
$w MED00194912 $t Blood advances $x 2473-9537 $g Roč. 8, č. 2 (2024), s. 369-377
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38214949 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423160032 $b ABA008
999    __
$a ok $b bmc $g 2081498 $s 1217298
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 8 $c 2 $d 369-377 $e 20240123 $i 2473-9537 $m Blood advances $n Blood Adv $x MED00194912
LZP    __
$a Pubmed-20240412

Find record

Citation metrics

Archiving options